Halozyme (HALO) — insider trading
Health Care · NASDAQ
Halozyme (HALO) has 57 reported SEC Form 4 insider transactions in our data, including 27 open-market sales among the most recent 57 (latest 2026-07-08).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-08 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Option exercise / conversion (derivative) | 1,923 | $12.07 | $23.2K | Form 4 |
| 2026-07-08 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Open-market sale | 1,035 | $80.19 | $83.0K | Form 4 |
| 2026-07-08 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Open-market sale | 888 | $79.28 | $70.4K | Form 4 |
| 2026-07-08 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Option exercise / conversion | 1,923 | $12.07 | $23.2K | Form 4 |
| 2026-07-01 | Connaughton Bernadette | Director | Open-market sale | 625 | $77.21 | $48.3K | Form 4 |
| 2026-07-01 | Connaughton Bernadette | Director | Open-market sale | 1,000 | $76.40 | $76.4K | Form 4 |
| 2026-07-01 | Snellgrove Darren | Officer (SVP, Chief Financial Officer) | Grant / award / vesting (derivative) | 127,432 | $0.00 | $0 | Form 4 |
| 2026-07-01 | Snellgrove Darren | Officer (SVP, Chief Financial Officer) | Grant / award / vesting (derivative) | 41,554 | $0.00 | $0 | Form 4 |
| 2026-07-01 | RAMSAY DAVID A | Officer (EVP, PRESIDENT, DRUG DELIVERY) | Grant / award / vesting (derivative) | 39,823 | $0.00 | $0 | Form 4 |
| 2026-07-01 | RAMSAY DAVID A | Officer (EVP, PRESIDENT, DRUG DELIVERY) | Grant / award / vesting (derivative) | 16,232 | $0.00 | $0 | Form 4 |
| 2026-06-30 | RAMSAY DAVID A | Officer (EVP, PRESIDENT, DRUG DELIVERY) | Option exercise / conversion (derivative) | 10,000 | $0.00 | $0 | Form 4 |
| 2026-06-30 | RAMSAY DAVID A | Officer (EVP, PRESIDENT, DRUG DELIVERY) | Shares withheld for taxes / exercise cost | 5,408 | $78.27 | $423.3K | Form 4 |
| 2026-06-30 | RAMSAY DAVID A | Officer (EVP, PRESIDENT, DRUG DELIVERY) | Option exercise / conversion | 10,000 | $0.00 | $0 | Form 4 |
| 2026-06-29 | Krishnan Mahesh | Director | Option exercise / conversion (derivative) | 7,304 | $0.00 | $0 | Form 4 |
| 2026-06-29 | Krishnan Mahesh | Director | Open-market sale | 7,304 | $75.00 | $547.8K | Form 4 |
| 2026-06-29 | Krishnan Mahesh | Director | Option exercise / conversion | 7,304 | $38.46 | $280.9K | Form 4 |
| 2026-06-12 | Snyder Mark Howard | Officer (SVP, CHIEF LEGAL OFFICER) | Option exercise / conversion (derivative) | 5,034 | $0.00 | $0 | Form 4 |
| 2026-06-12 | Snyder Mark Howard | Officer (SVP, CHIEF LEGAL OFFICER) | Shares withheld for taxes / exercise cost | 2,715 | $69.50 | $188.7K | Form 4 |
| 2026-06-12 | Snyder Mark Howard | Officer (SVP, CHIEF LEGAL OFFICER) | Option exercise / conversion | 5,034 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Option exercise / conversion (derivative) | 10,000 | $12.07 | $120.7K | Form 4 |
| 2026-06-03 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Open-market sale | 6,100 | $69.69 | $425.1K | Form 4 |
| 2026-06-03 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Open-market sale | 2,000 | $68.74 | $137.5K | Form 4 |
| 2026-06-03 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Open-market sale | 1,500 | $67.68 | $101.5K | Form 4 |
| 2026-06-03 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Open-market sale | 400 | $66.37 | $26.5K | Form 4 |
| 2026-06-03 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Option exercise / conversion | 10,000 | $12.07 | $120.7K | Form 4 |
| 2026-06-02 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Option exercise / conversion (derivative) | 20,000 | $12.07 | $241.4K | Form 4 |
| 2026-06-02 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Open-market sale | 3,400 | $66.75 | $226.9K | Form 4 |
| 2026-06-02 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Open-market sale | 16,600 | $66.31 | $1.10M | Form 4 |
| 2026-06-02 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Option exercise / conversion | 20,000 | $12.07 | $241.4K | Form 4 |
| 2026-06-01 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Option exercise / conversion (derivative) | 20,000 | $12.07 | $241.4K | Form 4 |
| 2026-06-01 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Open-market sale | 5,401 | $68.35 | $369.1K | Form 4 |
| 2026-06-01 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Open-market sale | 12,989 | $67.41 | $875.6K | Form 4 |
| 2026-06-01 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Open-market sale | 1,610 | $66.39 | $106.9K | Form 4 |
| 2026-06-01 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Option exercise / conversion | 20,000 | $12.07 | $241.4K | Form 4 |
| 2026-06-01 | Connaughton Bernadette | Director | Open-market sale | 1,625 | $66.21 | $107.6K | Form 4 |
| 2026-05-13 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Option exercise / conversion (derivative) | 10,000 | $12.07 | $120.7K | Form 4 |
| 2026-05-13 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Open-market sale | 600 | $70.81 | $42.5K | Form 4 |
| 2026-05-13 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Open-market sale | 3,950 | $69.79 | $275.7K | Form 4 |
| 2026-05-13 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Open-market sale | 3,350 | $68.88 | $230.7K | Form 4 |
| 2026-05-13 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Open-market sale | 2,100 | $68.10 | $143.0K | Form 4 |
| 2026-05-13 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Option exercise / conversion | 10,000 | $12.07 | $120.7K | Form 4 |
| 2026-05-12 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Option exercise / conversion (derivative) | 20,000 | $12.07 | $241.4K | Form 4 |
| 2026-05-12 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Open-market sale | 2,800 | $73.12 | $204.7K | Form 4 |
| 2026-05-12 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Open-market sale | 5,900 | $72.15 | $425.7K | Form 4 |
| 2026-05-12 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Open-market sale | 9,802 | $71.37 | $699.6K | Form 4 |
| 2026-05-12 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Open-market sale | 1,398 | $70.29 | $98.3K | Form 4 |
| 2026-05-12 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Open-market sale | 100 | $67.85 | $6.8K | Form 4 |
| 2026-05-12 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Option exercise / conversion | 20,000 | $12.07 | $241.4K | Form 4 |
| 2026-05-11 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Option exercise / conversion (derivative) | 20,000 | $12.07 | $241.4K | Form 4 |
| 2026-05-11 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Open-market sale | 6,700 | $66.33 | $444.4K | Form 4 |
| 2026-05-11 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Open-market sale | 3,575 | $65.46 | $234.0K | Form 4 |
| 2026-05-11 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Open-market sale | 9,725 | $64.63 | $628.5K | Form 4 |
| 2026-05-11 | Torley Helen | Director, Officer (PRESIDENT AND CEO) | Option exercise / conversion | 20,000 | $12.07 | $241.4K | Form 4 |
| 2026-05-05 | Krishnan Mahesh | Director | Grant / award / vesting (derivative) | 6,040 | $0.00 | $0 | Form 4 |
| 2026-05-05 | Krishnan Mahesh | Director | Grant / award / vesting | 3,796 | $0.00 | $0 | Form 4 |
| 2026-05-05 | Posard Matthew L. | Director | Grant / award / vesting (derivative) | 6,040 | $0.00 | $0 | Form 4 |
| 2026-05-05 | Posard Matthew L. | Director | Grant / award / vesting | 3,796 | $0.00 | $0 | Form 4 |
Ask the chat about HALO's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Halozyme (HALO).
Last updated 2026-07-08 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.